Clinical Trial

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-03-21; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2026-03-12
Trial Details
NCT Number NCT06892639
Lead Sponsor Castle Creek Biosciences, LLC.
Collaborators: Prosoft Clinical
Conditions Dystrophic Epidermolysis Bullosa
Enrollment 32 participants
Start Date 2025-03-27
Primary Completion 2027-09 (estimated)
Study Completion 2042-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-13